In a recent interview, JPMorgan Chase's CEO, Jamie Dimon, reflected on his decision not to pursue the presidency, sharing that it would have meant leaving his family behind for an extended period. Dimon emphasized the personal toll public office can take, remarking, "They’d be saying, 'See ya, dad'" during his tenure. Citing his age and health issues as significant factors, Dimon stated, "At 68 years old, it just didn’t seem like the right thing for me to do." His remarks come amid substantial financial updates from drugmakers, including Eli Lilly, which reported robust fourth-quarter figures, including a 20% year-over-year growth in non-incretin revenues. While sales for its incretin medications, such as Mounjaro, fell short of estimates, the company remains optimistic. Lilly forecasts revenues of $58.0 billion to $61.0 billion for 2025, anticipating significant contributions from new products and ongoing sales of Mounjaro alongside other therapies in its portfolio.
